From November 2016 to May 2018, 338 patients underwent LSG at 2 institutions. Seventeen patients were detected with unexpected coincidental GISTs during the LSG, resulting in an incidence of 5%.
A total of 14 females with GISTs (84%) and 3 males with GISTs (16%) constituted the patients. The age of patients with discovered GIST ranged from 21 to 41 years with the mean ± SD of 31.91 ± 5.70 and a median of 31 (21 - 41). The median preoperative weight range was 134 (112 - 170) kg with the mean ± SD preoperative BMI of 41.16 ± 6.35 kg/m2.
All basic characteristics of operated patients (n = 338) are listed in
Table 1.
| Patients’ Characteristics | The Operated Patients (N = 338). No. (%) |
|---|
| Sex | |
| Male | 254 (75.1) |
| Female | 84 (24.9) |
| Age, y | |
| Mean ± SD | 31.91 ± 5.70 |
| Median (range) | 32 (21 - 41) |
| Comorbidities | |
| Absent | 139 (41.1) |
| Present | 199 (58.9) |
| Type II DM | 122 (36.1) |
| Hypertension | 124 (36.7) |
| Dyslipidemia | 123 (36.4) |
| History of breast cancer | 1 (0.3) |
| History of ovarian cancer | 1 (0.3) |
| Preoperative weight, kg | |
| Mean ± SD | 137.39 ± 20.01 |
| Median (range) | 134 (112 – 170) |
| Preoperative BMI, kg/m2 | |
| Mean ± SD | 41.16 ± 6.35 |
| Median (range) | 37 (35 - 50) |
| Preoperative dyspepsia | |
| Absent | 100 (29.6) |
| Present | 238 (70.4) |
| Preoperative chronic gastritis | |
| Absent | 258 (76.3) |
| Present | 80 (23.7) |
| Preoperative Helicobacter pylori | |
| Absent | 278 (82.2) |
| Present | 60 (17.8) |
| Operative time, min | |
| Mean ± SD | 49.45 ± 4.16 |
| Median (range) | 50 (5 - 57) |
| Incidental GIST | |
| Absent | 321 (95) |
| Present | 17 (5) |
Abbreviations: DM, diabetes mellitus; SD, standard deviation.
When analyzing the presence of comorbidities in GIST patients, 36.7% (n = 124) had a history of hypertension, 8 patients had GISTs with type II diabetes mellitus (DM), and 36.1% (n = 122) were involved with dyslipidemia, from which 8 had GISTs. Only one female patient reported having a history of ovarian and breast cancer. At the time of examination and admission, she was disease-free.
Generally, 17% of patients (n = 12) reported dyspepsia as the main complaint in GIST patients. None of the patients had symptoms, laboratory tests, or imaging that helped to settle a preoperative diagnosis of GIST.
All patients underwent preoperative UGIT as a part of the preoperative workup. The findings were non-suggestive of GIST in any case; 18 patients were excluded due to a hiatus hernia. Superficial chronic gastritis and gastroduodenitis were some of the most common findings encountered in the endoscopic biopsy. Only 5 patients with GIST patients (30%) showed that gastritis; 19% of GIST patients were Helicobacter pylori-positive, which was treated before surgery by triple therapy. But many cases recorded H. pylori positive postoperatively.
The mean ± SD of operative time was 49.45 ± 4.16 minutes and the median (range) was 50 (41 - 57) minutes. No change in the already planned procedure was necessary upon coincidental detection of GISTs.
The Clinico-pathological data of discovered incidental GIST (n = 17) were illustrated in
Table 2.
| Clinico-Pathological Data | Incidental GIST (N = 17), No. (%) |
|---|
| Location of tumors | |
| Fundus and cardia | 15 (88.2) |
| Body | 2 (11.8) |
| Tumor extension | |
| Intraluminal | 2 (11.8) |
| Extraluminal | 12 (70.6) |
| Transluminal | 3 (17.6) |
| Number of tumors | |
| Single | 17 (100) |
| Tumor size, cm | |
| Mean ± SD | 1.41 ± 0.40 |
| Median (range) | 1.50 (0.60 - 2.10) |
| Mitotic index | |
| Low rate | 16 (94.1) |
| High rate | 1 (5.9) |
| CD 117 | |
| Negative | 1 (5.9) |
| Positive | 16 (94.1) |
| DOG1 | |
| Negative | 2 (11.8) |
| Positive | 15 (88.2) |
| SMA | |
| Negative | 17 (100) |
| S100 | |
| Negative | 1 (5.9) |
| Positive | 16 (94.1) |
| Tumor rupture | |
| Negative | 16 (94.1) |
| Positive | 1 (5.9) |
| Safety margin, cm | |
| Marginal margin ≤ 1 | 3 (17.6) |
| Wide margin > 1 - 2 | 14 (82.4) |
| Surgical margin | |
| Negative | 15 (88.2) |
| Positive | 2 (11.8) |
| Regional lymph nodes | |
| Not revealed | 17 (100) |
| T | |
| T1 | 15 (88.2) |
| T2 | 2 (11.8) |
| AJCC TNM | |
| Stage IA | 16 (94.4) |
| Stage IIA | 1 (5.9) |
| Recurrence | |
| Absent | 17 (100) |
Abbreviations: CD 117, proto-oncogene c-kit; DOG1, gene highly expressed in GIST, subsequently found to encode calcium-activated chloride channels in the interstitial cells of Cajal; S100, Schwann cell marker; SMA, smooth muscle actin.
Location of the Tumor: Most of the GISTs were found along the greater curvature, mainly in the fundus in 15 patients (88.2%) and only 2 patients with GISTs in the body.
Histopathological examination was performed with an Immunohistochemically essay. The tumor was of spindle cell in 88%. Mitotic rate was calculated and 16 patients (94.1%) had a low rate of 0 - 4/5 mm2 high power field or fewer mitoses per 5 mm2 and 1 patient (5.9%) had more than 5 mitoses per 5 mm2.
Tumor size ranged from 0.5 cm T1 to 2.1 cm T2 with majority T1; 15 patient (88.2%) and 2 patients fall in T2 (11.8%). The staging was done according to TNM; stage IA: 16 patients and stage IIA: 1 patient.
Growth pattern and tumor extension: 12 patients (70.6%) have an extraluminal tumor, 3 transluminal, and 2 intraluminal.
Tumor Rupture: Only 1 patient was found with tumor rupture, who was a positive margin status.
Immunohistochemically: 94.1% were positive for CD117, 88.2% were positive for DOG1, 94.1 % were positive for S100 protein, and 100% were negative for SMA.
Safety margin (
Figure 5) was marginal margin ≤ 2 cm for 3 patients to avoid incorporation in staple line and wide margin in 14 patients (82.3%) ≥ 2 cm. Resection margin status was assessed in biopsy and revealed positive margin R1 for 2 patients, in which their safety margin was only 1 cm or less and one of them had high mitotic rate staged as IIA.
Pie chart shows safety margin among 13 incidentally
Margin status revealed 15 patients with negative margin (R0), 2 patients (11.8%) with positive margin (R1), 1 of them underwent re-exploration, where total gastrectomy and esophagojejunostomy was performed; the other patient refused intervention and received Imatinib. The patient received treatment (400 mg/day) 1 year after the patients were informed about the effects, duration of Imatinib, and prognosis. All patients underwent a CT follow-up at 3 - 6 months, upper GIT endoscopy 12 and 24 months follow-up; chronic superficial gastritis was one of the most common histological findings in 93% of cases; 82% of them showed atrophic type even in the patient receiving Imatinib. CT abdomen and pelvis with oral and intravenous contrast was performed in all patients, showing no evidence of metastasis even in the patient who received Imatinib.